Please provide your email address to receive an email when new articles are posted on . In an analysis of data from two phase 3, multicenter studies of 1,217 adult patients randomized to the ...

Richard Adler, MD, FACS, leads a discussion on real-world signs, symptoms and patient reactions associated with the treatment for DED. This is a video synopsis/summary of a Post Conference ...

DENVER – Treatment with the mitochondrial reactive oxygen species scavenger Visomitin resulted in reduced corneal staining and improved visual function in patients with dry eye, according to a study ...

DALLAS - Aug. 20, 2007 - Lissamine green sounds like the latest cleaning sensation being hawked on television and probably not something you would want to get in your eyes. But a few properly placed ...

HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology ...

Richard Adler, MD, FACS, discusses the Switch trial which compared OTX-101 (cyclosporine ophthalmic solution 0.09%) vs cyclosporine ophthalmic emulsion 0.05% (Restasis) in patients with dry eye ...

ARLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Oculis is forging ahead with its precision medicine approach to treating dry eye disease, outlining plans to finalize a phase 3 study after seeing some signs of efficacy in a subpopulation in its ...

A phospholipid nanoemulsion–based ocular lubricant applied twice daily is well tolerated, improves the stability of tear film, and alleviates symptoms in patients with dry eye disease. Researchers ...

Corneal ulcers are open sores that develop on the cornea, the transparent layer at the front of the eye. These ulcers may form if a person has an eye infection, very dry eyes, or sleeps with their ...